Generic Medicine Info
May be taken with or without food. May be taken w/ meals if GI upset occurs.
Glaucoma, gastrointestinal obstruction (e.g. pyloric or duodenal obstruction), stenosing peptic ulcer, megaesophagus, prostatic hypertrophy, bladder neck obstruction, myasthenia gravis; tardive dyskinesia (orphenadrine hydrochloride).
Special Precautions
Patient with CV disease (e.g. heart failure, cardiac decompensation, coronary insufficiency, tachycardia, cardiac arrhythmias), thyrotoxicosis, hypertension, history of drug abuse or acute alcoholism, porphyria, micturition difficulties. Avoid abrupt withdrawal. Some products or formulations are not interchangeable; refer to specific product guideline for further information. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause blurred vision, dizziness or slight euphoria, if affected, do not drive or operate machinery. Monitoring Parameters If for prolonged use, monitor blood, urine, and LFTs.
Adverse Reactions
Significant: CNS depression, euphoria (increased risk for drug abuse and dependence). Blood and lymphatic system disorders: Very rarely, aplastic anaemia. Cardiac disorders: Palpitation, tachycardia. Eye disorders: Disturbance of visual accommodation. Gastrointestinal disorders: Dry mouth, gastrointestinal disturbances, nausea, constipation. Immune system disorders: Hypersensitivity reaction. Rarely, anaphylaxis (IM). Nervous system disorders: Dizziness, drowsiness, restlessness. Psychiatric disorders: Confusion, hallucination. Renal and urinary disorders: Micturition difficulties.
Drug Interactions
May enhance the sedative effect with other sedatives. May cause anxiety, confusion, tremors with propoxyphene. May increase the antimuscarinic effects with antihistamines, antispasmodics, TCAs, phenothiazines, dopaminergic antiparkinsonian drugs (e.g. amantadine), antiarrhythmics (e.g. disopyramide). Enhanced effect with anticholinergic drugs.
CIMS Class
Antiparkinsonian Drugs / Muscle Relaxants
Disclaimer: This information is independently developed by CIMS based on orphenadrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in